Amber warning for the UK's access to new medicines post Brexit

June 27, 2017

In an editorial to be published on Tuesday 27th June 2017 in the journal ecancermedicalscience, Anthony Hatswell of BresMed (an independent health economics consultancy) and University College London, explores the consequences of a British exit from the European Medicines Agency (EMA) as a result of Brexit, and what this will mean for pharmaceutical regulation and future access to medicines for UK citizens.

The EMA is a decentralised agency of the European Union (EU), located in London which is responsible for ensuring that all medicines available on the EU market are safe, effective and of high quality. The future of EMA's headquarters in London is the focus of much speculation at present, as is Britain's future role in the EMA.

The editorial explores how a British withdrawal from the EMA will likely delay the availability of new medicines to the UK market. There is already a reluctance in the UK to fund next generation treatments (for example combination therapies for cancer)1 and the UK has a sketchy track record on handling access such as the much lambasted 'Cancer Drugs Fund'.2

The author argues that removal from the EMA jeopardizes access not just to emerging treatment but also their cheaper off brand counterparts once patents expire. In the long term this would be a source of massive harm to patients.

Should the UK leave the European Medicines Agency the author voices his concern that current calculations of the cost of Brexit have not factored in the cost for duplicating the functions of the EMA - not only in licensing new medicines, but inspecting manufacturing plants worldwide.

The author states: "This is such an important topic, and at the moment there appears to be no policy whatsoever.

"There is a sense that the UK could try and emulate the US model, which has a national system for drug regulation managed by the Food and Drug Administration (FDA) who lead the way in access. However this outcome is unrealistic as the US is a special case due to high prices, a large patient population, few restrictions to access, and direct to consumer advertising3. A more likely outcome can be seen with Japan's sovereign regulator, which is despite a market size twice the size of the UK due to both population and GDP, lags the EU (including the UK) in timely access to novel medicines."

Mr Hatswell argues that one potential solution could see the UK's Medicines & Healthcare products Regulatory Agency (MHRA) remaining a part of the EMA, but also given the freedom to adopt decisions from other regulators (such as the FDA). Such an arrangement could actually speed access to medicines and keep the UK at the forefront of medical technology.

On a positive note the author concludes that "With careful planning and collaboration - the UK can maintain or even advance its position as a leader in life sciences. Not only do patients require [this], the life sciences sector is a large source of well-paid employment, and a large net exporter for the UK. As long as ideology does not trump the benefits of cooperation it does not have to be the end of a productive relationship that has done great things for patients across Europe."
-end-
1: http://www.cancerresearchuk.org/funding-for-researchers/research-features/2016-08-10-health-economics-the-cancer-drugs-cost-conundrum

2: http://www.bbc.co.uk/news/health-39711137

3: Drugs and Devices: Comparison of European and U.S. Approval Processes, Gail A. Van Norman. http://www.sciencedirect.com/science/article/pii/S2452302X16300638

Editor's Notes

This information is embargoed until 10.00 am BST Tuesday 27 June 2017.

The paper has been authored by Anthony James Hatswell1, 2

1 BresMed, Sheffield, UK
2 Department of Statistical Science, University College London, UK

Anthony Hatswell is available for interviews.

For a copy of the final version of the paper, to set up an interview or for more information please contact Karen Watts, Head of Communications, ecancer

Citation information: Hatswell A (2017) ecancer 11:ed67 doi:10.3332/ecancer.2017.ed67

About ecancermedicalscience (ecancer.org)

ecancermedicalscience (ecancer) is the official open access journal of the Organisation of European Cancer Institutes (OECI) and the European Institute of Oncology (IEO), Milan.

The journal was established in 2007 by Professor Umberto Veronesi and Professor Gordon McVie with the mission to break down the financial barriers to accessing cancer research and education.

The journal is not for profit and only charges authors an article publication fee if they have specific funding for publishing. So far over 2000 authors have published for free. The journal is funded by the Swiss based ECMS foundation, educational grants, sponsorship and charitable donations.

ecancermedicalscience

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.